Business
Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin....
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials,...
Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to...
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of...
This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind...
In today's episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA. ATMA is a...
Modernized psychedelic medicine is coming, whether you like it or not, so here are five of the most exciting next-generation...
This week in psychedelic business news: New patents; another Health Canada SAP Approval; and legal psilocybin rules for Oregon....
Even if you can't be there in person, it's not too late to get a discounted pass to tune in...